Helius Medical Technologies, Inc.’s Dr. Antonella Favit-Van Pelt to Present at 4th International Brain Stimulation Conference on December 9
06 December 2021 - 11:05PM
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the
“Company”), a neurotech company focused on neurological wellness,
today announced that Chief Medical Officer Antonella Favit-Van
Pelt, M.D., Ph.D. will be presenting at the 4th International Brain
Stimulation Conference, taking place December 6 - 9 in Charleston,
S.C. The conference is organized by Elsevier, a global leader in
information and analytics, and brings together experts in the field
of brain stimulation across a wide range of disciplines.
Alongside three other key opinion leader
clinicians, Dr. Favit-Van Pelt will be part of a Thursday symposium
titled “Recently authorized by the FDA—Novel Brain Stimulation
treatments coming to a clinic near you.” During the session, Dr.
Favit-Van Pelt will introduce the research that led to the FDA
authorization of translingual nerve stimulation for gait
disturbance in multiple sclerosis in a presentation titled
“Portable neuromodulation stimulator (PoNS) device therapy improves
gait function in patients with multiple sclerosis.” Helius received
marketing authorization for the use of PoNS in the treatment of
gait deficit due to mild-to-moderate symptoms of MS in March 2021
and, in August 2021, received Breakthrough Designation for the
treatment of dynamic gait and balance deficits resulting from a
stroke.
Dr. Favit-Van Pelt’s co-panelists will include
Dr. Gregory Sahlem of Stanford University, Dr. Abraham Zangen of
Ben-Gurion University in Israel, and Dr. Teresa Kimberley of MGH
Institute of Health Professions. The symposium will run from 1:30
to 3:30 PM, eastern standard time.
About Antonella Favit-Van Pelt, MD,
PhD
Dr. Favit-Van Pelt is a rare disease expert and
pioneer in the field of applied theragnostics for the development
of disease-modifying treatments. A board-certified neurologist, she
holds a PhD in Pharmacology and has more than 20 years of drug
development expertise in the pharmaceutical industry and academia.
She started her clinical practice activity in 1994 with specialist
clinics in Europe where she continues as a specialist consultant
managing patients with movement disorders and rare neuromuscular
disorders. Dr. Favit-Van Pelt currently serves as Chief Medical
Officer of Helius.
About Helius Medical Technologies,
Inc.
Helius Medical Technologies is a leading
neurotech company in the medical device field focused on neurologic
deficits using non-implantable platform technologies that amplify
the brain’s ability to compensate and promotes neuroplasticity,
aiming to improve the lives of people dealing with neurologic
diseases. The Company’s first commercial product is the Portable
Neuromodulation Stimulator (PoNS). For more information, visit
www.heliusmedical.com.
About the PoNS Device and PoNS
Therapy
The Portable Neuromodulation Stimulator (PoNS)
is an innovative non-surgical medical device, inclusive of a
controller and mouthpiece, which delivers electrical stimulation to
the surface of the tongue to improve balance and gait. The PoNS
device is indicated for use in the United States as a short-term
treatment of gait deficit due to mild-to-moderate symptoms from
multiple sclerosis (“MS”) and is to be used as an adjunct to a
supervised therapeutic exercise program in patients 22 years of age
and over by prescription only. Helius is advancing PoNS
post-approval research in MS through a recently launched
Therapeutic Experience Program (TEP).
PoNS is also authorized for sale in Canada for
two indications: (i) PoNS is authorized as a short-term treatment
(14 weeks) of chronic balance deficit due to mild-to-moderate
traumatic brain injury (“mmTBI”) and is to be used in conjunction
with physical therapy; and (ii) PoNS is authorized for use as a
short term treatment (14 weeks) of gait deficit due to mild and
moderate symptoms from MS and is to be used in conjunction with
physical therapy. PoNS is also authorized for sale in Australia for
short term use by healthcare professionals as an adjunct to a
therapeutic exercise program to improve balance and gait.
Cautionary Disclaimer
Statement
Certain statements in this news release are not
based on historical facts and constitute forward-looking statements
or forward-looking information within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995 and Canadian
securities laws. All statements other than statements of historical
fact included in this news release are forward-looking statements
that involve risks and uncertainties. Forward-looking statements
are often identified by terms such as “believe,” “expect,”
“continue,” “will,” “goal,” “aim” and similar expressions.
There can be no assurance that such statements
will prove to be accurate and actual results and future events
could differ materially from those expressed or implied by such
statements. Important factors that could cause actual results to
differ materially from the Company’s expectations include risks
detailed from time to time in the “Risk Factors” section of the
Company’s Annual Report on Form 10-K for the year ended December
31, 2020, its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2021 and its other filings with the United States
Securities and Exchange Commission and the Canadian securities
regulators, which can be obtained from either at www.sec.gov or
www.sedar.com.
The reader is cautioned not to place undue
reliance on any forward-looking statement. The forward-looking
statements contained in this news release are made as of the date
of this news release and the Company assumes no obligation to
update any forward-looking statement or to update the reasons why
actual results could differ from such statements except to the
extent required by law.
Investor Relations Contact
Lisa M. Wilson, In-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2024 to May 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From May 2023 to May 2024